309 related articles for article (PubMed ID: 10562412)
1. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
[TBL] [Abstract][Full Text] [Related]
2. Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding.
Haining RL; Jones JP; Henne KR; Fisher MB; Koop DR; Trager WF; Rettie AE
Biochemistry; 1999 Mar; 38(11):3285-92. PubMed ID: 10079071
[TBL] [Abstract][Full Text] [Related]
3. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.
Haining RL; Hunter AP; Veronese ME; Trager WF; Rettie AE
Arch Biochem Biophys; 1996 Sep; 333(2):447-58. PubMed ID: 8809086
[TBL] [Abstract][Full Text] [Related]
4. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9.
Mancy A; Dijols S; Poli S; Guengerich P; Mansuy D
Biochemistry; 1996 Dec; 35(50):16205-12. PubMed ID: 8973193
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.
Thijssen HH; Flinois JP; Beaune PH
Drug Metab Dispos; 2000 Nov; 28(11):1284-90. PubMed ID: 11038154
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone.
Takahashi H; Sato T; Shimoyama Y; Shioda N; Shimizu T; Kubo S; Tamura N; Tainaka H; Yasumori T; Echizen H
Clin Pharmacol Ther; 1999 Dec; 66(6):569-81. PubMed ID: 10613612
[TBL] [Abstract][Full Text] [Related]
7. The substrate binding site of human liver cytochrome P450 2C9: an NMR study.
Poli-Scaife S; Attias R; Dansette PM; Mansuy D
Biochemistry; 1997 Oct; 36(42):12672-82. PubMed ID: 9335524
[TBL] [Abstract][Full Text] [Related]
8. Substrate probe for the mechanism of aromatic hydroxylation catalyzed by cytochrome P450.
Darbyshire JF; Iyer KR; Grogan J; Korzekwa KR; Trager WF
Drug Metab Dispos; 1996 Sep; 24(9):1038-45. PubMed ID: 8886617
[TBL] [Abstract][Full Text] [Related]
9. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies.
Kunze KL; Wienkers LC; Thummel KE; Trager WF
Drug Metab Dispos; 1996 Apr; 24(4):414-21. PubMed ID: 8801056
[TBL] [Abstract][Full Text] [Related]
10. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase).
Jones BC; Hawksworth G; Horne VA; Newlands A; Morsman J; Tute MS; Smith DA
Drug Metab Dispos; 1996 Feb; 24(2):260-6. PubMed ID: 8742240
[TBL] [Abstract][Full Text] [Related]
11. Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function.
Ridderström M; Masimirembwa C; Trump-Kallmeyer S; Ahlefelt M; Otter C; Andersson TB
Biochem Biophys Res Commun; 2000 Apr; 270(3):983-7. PubMed ID: 10772937
[TBL] [Abstract][Full Text] [Related]
12. Metabolic enantiomeric interactions: the inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin.
Kunze KL; Eddy AC; Gibaldi M; Trager WF
Chirality; 1991; 3(1):24-9. PubMed ID: 2039681
[TBL] [Abstract][Full Text] [Related]
13. Warfarin analog inhibition of human CYP2C9-catalyzed S-warfarin 7-hydroxylation.
Zhang ZY; Kerr J; Wexler RS; Li HY; Robinson AJ; Harlow PP; Kaminsky LS
Thromb Res; 1997 Nov; 88(4):389-98. PubMed ID: 9526963
[TBL] [Abstract][Full Text] [Related]
14. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
Yamazaki H; Inoue K; Shimada T
Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
[TBL] [Abstract][Full Text] [Related]
15. Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.
Ablin J; Cabili S; Lagziel A; Peretz H
Isr Med Assoc J; 2002 Feb; 4(2):139-41. PubMed ID: 11875991
[No Abstract] [Full Text] [Related]
16. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.
Hanatani T; Fukuda T; Ikeda M; Imaoka S; Hiroi T; Funae Y; Azuma J
Pharmacogenomics J; 2001; 1(4):288-92. PubMed ID: 11908770
[TBL] [Abstract][Full Text] [Related]
17. Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model.
Hutzler JM; Hauer MJ; Tracy TS
Drug Metab Dispos; 2001 Jul; 29(7):1029-34. PubMed ID: 11408370
[TBL] [Abstract][Full Text] [Related]
18. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
Drug Metab Dispos; 2000 Aug; 28(8):994-1002. PubMed ID: 10901712
[TBL] [Abstract][Full Text] [Related]
19. Microbial models of mammalian metabolism: production of novel alpha-diketone metabolites of warfarin and phenprocoumon using Aspergillus niger.
Rizzo JD; Davis PJ
Xenobiotica; 1988 Dec; 18(12):1425-37. PubMed ID: 3245234
[TBL] [Abstract][Full Text] [Related]
20. Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner.
Liu KH; Kim MJ; Jung WM; Kang W; Cha IJ; Shin JG
Drug Metab Dispos; 2005 Feb; 33(2):209-13. PubMed ID: 15537834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
